Ionis Pharmaceuticals Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $5.64B
  • PE -16
  • Debt $44.47M
  • Cash $334.61M
  • EV $5.35B
  • FCF -$370.91M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$358.81M
EBIT-$355.80M
ROE-54%
ROA-12%
FCF-$370.91M
Equity$662.47M
Growth Stability-384%
PE-15.72
PEG3.38
PB8.52
P/FCF-15.21
P/S7.03
Price/Cash0.06
Debt/Equity0.07
Debt/FCF-0.12
Net Margins-73%
Gross Margins99%
Op. Margins-44%
Earnings CAGR1%
Sales Growth YoY-7%
Sales Growth QoQ-41%
Sales CAGR15%
FCF CAGR0%
Equity CAGR11%
Earnings Stability0
Earnings Growth YoY-5%
Earnings Growth QoQ112%
Earnings CAGR 5Y-5%
Sales CAGR 5Y-5%
FCF CAGR 5Y-3%
Equity CAGR 5Y-28%
Earnings CAGR 3Y-2%
Sales CAGR 3Y-2%
FCF CAGR 3Y3%
Equity CAGR 3Y-24%
Market Cap$5.64B
Revenue$803.07M
Assets$3.08B
Total Debt$44.47M
Cash$334.61M
Shares Outstanding146.7M
EV5.35B
Earnings Score6%
Moat Score2%
Safety Score33%
Final Score14%
Working Capital2.41B
Current Ratio8.91
Shares Growth 3y1%
Equity Growth QoQ151%
Equity Growth YoY110%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

SEC Filings

Direct access to Ionis Pharmaceuticals Inc (IONS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Ionis Pharmaceuticals Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Ionis Pharmaceuticals Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%
Stability 0%
loading chart...

Ionis Pharmaceuticals Inc Discounted Cash Flow

Fully customizable DCF calculator online for Ionis Pharmaceuticals Inc.

= -$3.7B
012345678910TV
fcf-$371M-$371M-$372M-$372M-$373M-$373M-$374M-$374M-$375M-$375M-$375M-$3.8B
DCF-$338M-$307M-$280M-$255M-$232M-$211M-$192M-$175M-$159M-$145M-$1.4B
Value-$3.7B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201405/201512/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-18%--31%-25%-3%36%26%-67%-4%-46%-47%-73%
ROA---5%-5%2%-1%12%-5%-1%-10%-11%-12%
ROE---44%-87%-4%18%17%-58%-4%-47%-95%-54%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201405/201512/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--0.04-4.213.840.992.51.09K0-4.12-4.08-0.12
Debt over Equity0.01-05.041.280.490.47102.083.50.07
Growth Stability------100%-297%-384%---384%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201405/201512/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth--57%211%22%46%18%87%-35%11%-28%34%-5%
Earnings YoY growth----2%-80%-1K%37%-265%-94%843%36%-5%
Equity YoY growth----50%321%184%42%-50%-8%-26%-33%-28%
FCF YoY growth----987%-217%323%-47%-100%2K%-2K%14%-3%